The Heart Protection Study: Expanding the boundaries for high-risk coronary disease prevention

John A. Farmer, Antonio Gotto

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Clinical trial evidence strongly favors aggressive risk factor modification in the prevention of coronary artery disease (CAD). The latest landmark trial of therapy using a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is the Heart Protection Study (HPS) of simvastatin versus placebo in a cohort of patients at high risk for CAD. The HPS reported a number of highly significant reductions in the risk for major vascular events with treatment. It also provides new insights into the effects of statin therapy in patient subgroups, such as the elderly, women, and those with noncoronary vascular disease. These data are likely to have an important influence on the future of cardiovascular disease prevention.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalAmerican Journal of Cardiology
Volume92
Issue number1 SUPPL.
DOIs
StatePublished - Jul 3 2003

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The Heart Protection Study: Expanding the boundaries for high-risk coronary disease prevention'. Together they form a unique fingerprint.

Cite this